3.9 Evidence Behind the Case

Chart finding	The claim the module makes	Supporting evidence	How strong?
Sterile inflammation — the finding (Clue #3) Chapter 7	Inflammation can be started by the body’s own danger signals with no microbe present (sterile inflammation), and in the autoinflammatory diseases innate immune cells start it from inside themselves; in that setting a culture that grows nothing, attack after attack, is a feature of the disease, not a missed infection. FMF is the prototype. Honesty flag: canon records no culture in 1988–1990 and dates the clue only ‘Every workup’; the childhood instance the module uses is the normal appendix at fifteen (Stina’s own later word: ‘a sterile appendix’).	Chen and Nuñez 2010 (review) · Masters et al. 2009 (review) · GeneReviews NBK1227 · Heilig and Broz 2018	Concept — strong; its childhood evidence — thin, flagged
Autoinflammatory is not autoimmune Chapters 1, 7	The word ‘autoinflammatory’ was introduced with the discovery of TNFRSF1A mutations in TRAPS (1999) for recurrent, seemingly unprovoked inflammation with no high-titer autoantibodies and no antigen-specific T cells — innate immunity firing without a pathogen. Autoimmunity is the adaptive system reading ‘self’ as foreign. FMF belongs to the first family; a mistaken name tag (MHC, antibodies) is the second.	McDermott et al. 1999 (PubMed 10199409) · Masters et al. 2009	Definition and genetics — strong
FMF belly attacks mimic appendicitis — and many appendices come out normal Chapters 4, 7 and the 3.8 verdict	An FMF abdominal attack is peritonitis — fever with an inflamed peritoneumThe membrane lining the abdominal cavity and organs. — and can look like an acute abdomen. In 182 consecutive Israeli FMF patients, 40% had had an appendectomy (against 12–25% in the general population), and about 80% of those appendices were not inflamed (against about 20% in comparison series); a shift from diffuse pain to pain in the right lower quadrant best predicted a truly inflamed appendix. Honesty flag: one center’s cohort, of patients already diagnosed; it shows the pattern, not what happened inside her in 1990 — the chart’s later reading of her pain as peritoneal serositis is hindsight, and the module asks the question rather than copying that answer.	Lidar et al. 2008 (PubMed 18799086) · GeneReviews NBK1227	Cohort — moderate; her case — hindsight, flagged
Pyrin is a cytosolic sensor released when RhoA is switched off Chapter 7 (and 3.2, 3.6)	Pyrin is made on free ribosomesSmall structures responsible for protein synthesis, either free-floating or attached to the rough ER and sits in the cytosol of neutrophils, monocytes, eosinophils and dendritic cellsImmune cells in the epidermis that help fight infections. (lower in macrophages). While RhoA is active, PKN1 and PKN2 phosphorylate it (Ser208, Ser242) and 14-3-3 proteinsLarge molecules made of amino acids with various functions in the body. hold it off; when RhoA is inactivated — by bacterial toxins such as those of C. difficile — the hold lets go, pyrin nucleates ASC and caspase-1, and pro-IL-1β, pro-IL-18 and gasdermin D are cut. In FMF the thresholdThe minimum voltage needed to trigger an action potential. is lower: dephosphorylationremoval of a phosphate group from a molecule alone is enough to trip it — a sensor that fires too easily (gain of function), not a broken brake. Honesty flag: her own changed copy — and what one copy can do — is Module 4’s Chart Reveal; Module 3 does not name it.	Xu et al. 2014 (PubMed 24919149) · Park et al. 2016 (PubMed 27270401) · Gao et al. 2016 (PubMed 27482109) · Magnotti et al. 2019 (PubMed 31589380) · Heilig and Broz 2018 (PubMed 29148036) · UniProt O15553	Mechanism — strong (cell, mouse and patient-cell studies)
Colchicine, microtubules and the pyrin inflammasome Chapters 3, 7	Colchicine, an alkaloid from the autumn crocus (Colchicum autumnale — not a true crocus), binds tubulin and blocks microtubule assembly. In ordinary cells the pyrin inflammasome needs intact microtubules, so colchicine blocks it (the textbook account the module teaches). But FMF-associated pyrin variants lift that obligatory requirement in cell studies — in patients’ cells pyrin can still assemble with the rails disrupted — so colchicine’s clinical benefit in FMF likely also comes from its effects on neutrophils: fewer stick to vessel walls and migrate into tissue. It remains the first-line FMF treatment and prevents AA amyloidosis. Honesty flag: how colchicine prevents FMF attacks is not fully settled; the module teaches the wild-type microtubule dependence, says the variants need the rails less, and hedges the adhesion-and-migration share. Stina takes no colchicine anywhere in Modules 1–4; it is the narrator’s forward flash.	Van Gorp et al. 2016 (PubMed 27911804) · Gao et al. 2016 (PubMed 27482109) · Magnotti et al. 2019 (PubMed 31589380) · EULAR/PReS 2024 update (Ozen et al. 2025, PubMed 40234174)	Drug–tubulin binding and clinical benefit — strong; how it prevents FMF attacks — not settled, flagged
IL-1β’s door: no signal peptide, a gasdermin-D pore Chapter 4	IL-1β is made as a 31 kDa precursor with no signal peptide, on free ribosomes, and never enters the ER–Golgi. Caspase-1 cuts it and also cuts gasdermin D, whose N-terminal pieces open pores in the plasma membraneThe outer boundary of a cell that controls what enters and exits.; mature IL-1β leaves through those pores, from living cells as well as cells dying by pyroptosis. Honesty flag: unconventional secretionThe process of moving substances from the blood into the nephron tubule to be excreted in urine. of IL-1β has several proposed routes; gasdermin-D pores are the best supported, not the only one, and the module says so.	Auron et al. 1984 · Shi et al. 2015 (PubMed 26375003) · Kayagaki et al. 2015 · Evavold et al. 2018 (PubMed 29195811)	Mechanism — strong; ‘the only exit’ — not claimed, flagged
The classical route: acute-phase proteins and collagenA structural protein in the dermis that provides strength and elasticity. Chapters 2, 4	Secreted proteins carry a signal peptide that docks their ribosome on the rough ER; they are folded there, labeled in the Golgi (cis to trans) and shipped in vesicles that leave by exocytosisThe process of expelling materials from a cell via vesicles that fuse with the plasma membrane.. Hepatocytes send albuminA plasma protein that helps maintain osmotic pressure and transport substances., CRP, serum amyloid A, fibrinogen plasma protein converted into fibrin during blood clotting. and ApoA-I out this way, and IL-6 (with IL-1β and TNF) switches the mix toward the acute-phase proteins while albumin falls; fibroblasts export procollagen.	OpenStax A&P 2e, Chapter 3 · Gabay and Kushner 1999	Textbook and review — strong
K⁺ efflux is NLRP3’s trigger, not pyrin’s Chapter 6	Bacterial pore-forming toxins, extracellular ATPThe energy currency of cells used for muscle contraction. acting on P2X7, and crystals such as urate all activate the NLRP3 inflammasome through one common step: potassium(K⁺): Major ICF cation; essential for muscle and nerve function. leaving the cell. The pyrin inflammasome does not need it — pyrin reads RhoA. The Na⁺/K⁺ pump’s gradient is real and every cell spends it; it is a different sensor’s trigger.	Muñoz-Planillo et al. 2013 (PubMed 23809161) · Gao et al. 2016	Mechanism — strong
P-glycoprotein, CYP3A4 and colchicine with statins Chapter 6	Colchicine is pumped out of cells by P-glycoprotein (ABCB1), an ATP-powered efflux pump, and metabolized by CYP3A4 in the liver’s smooth ER. Strong CYP3A4 or P-gp inhibitors (clarithromycin, cyclosporine, some azoles) raise colchicine levels enough to cause fatal toxicity, and the label warns that atorvastatin, simvastatin and other statins and fibrates may add to colchicine’s myopathy and rhabdomyolysisBreakdown of muscle tissue releasing contents into the blood, can damage kidneys.. Honesty flag: in her story a statin (2026) was stopped before colchicine began, so no collision happened — narrator’s forward flash to Blood Vessels, Module 16.	COLCRYS (colchicine) prescribing information, US FDA label · Terkeltaub et al. 2011 (PubMed 21480191) · Wiggins et al. 2016 (AHA scientific statement, PubMed 27754879)	Label and pharmacokinetic studies — strong
Attacks on the first day of the period Chapters 1, 5 (and 3.3)	Menstruation is a recognized trigger of FMF attacks. Of 151 female patients with FMF at a Turkish pediatric rheumatology unit, 35 (23%) had menstruation-associated attacks; their disease had begun earlier (median 2.5 against 5 years), and dysmenorrhea was more common in them. An earlier Jerusalem study found menstruation-associated attacks in 7% of 141 women (as cited in the diary’s evidence section A cut or slice of the body or an organ for study.). Honesty flag: ordinary dysmenorrhea is common and not every menstrual flare meets attack criteria; Stina’s day-one pattern is her own calendar, read in hindsight, not a diagnosis.	Batu Akal et al., Rheumatology 2025 · Ben-Chetrit and Ben-Chetrit 2001 (PubMed 11305548)	Cohort — moderate; estimates vary widely
Legs that go numb under a desk Chapter 6	Sitting with the legs hanging presses on nerves and their blood supply; with less oxygen and fuel the Na⁺/K⁺ pump falls behind, the membrane cannot hold its charge, and the signal falters — pins and needles that clear when she stands and shakes them out. Honesty flag: this is general physiologyThe study of how the body functions., hedged, not an FMF finding and not a symptom of her disease; the nerve itself is Modules 8–9’s, and the cramp mechanism is Muscular 7.4’s.	OpenStax A&P 2e, Chapters 3 and 12	General physiology — flagged
An inflamed lining leaks protein, and waterThe universal solvent essential for life. follows Chapter 5	Inflammatory mediators (IL-1β, TNF, histamine, bradykinin) dilate vessels and open gaps between endothelial cells; plasmaThe liquid component of blood. protein escapes, the colloidA mixture where small particles are dispersed but not dissolved in a liquid. (oncotic) pressureThe force exerted by gases in the respiratory system, affecting airflow and gas exchange. difference of about 25–28 mmHg that holds water in the vessels shrinks, and a protein-rich exudate collects — unlike a transudate from low albumin or high pressure. An inflamed peritoneum also hurts because the parietal layer is sensitive. Honesty flag: no childhood effusion is recorded; the module says an inflamed lining may leak, never that hers did at fifteen.	OpenStax A&P 2e, Chapters 20 and 21	Physiology — strong; her childhood fluid — not recorded, flagged
What a 1988–1990 workup could and could not show Chapters 1, 4, 7	A teenager’s acute belly in 1990 could get a blood count with a differential, a urinalysis, plain X-rays and, increasingly, ultrasound; the Alvarado score (1986) built ‘fever, pain low on the right, white count up’ — fever, right-lower-quadrant tenderness, leukocytosis and a left shift — into a bedside rule for appendicitis. Pathology could say whether an appendix was inflamed. Nothing clinical could measure IL-1β, see pyrin, or test MEFV, which was not identified until 1997. Honesty flag: general laboratory history, hedged — canon records only ‘white count up’, with no number, and no culture.	Alvarado 1986 (PubMed 3963537) · French FMF Consortium 1997 · International FMF Consortium 1997 · Auron et al. 1984	History — moderate, hedged
Using up your credibility Chapter 1 (and the 3.8 branching scenario)	‘On the first visit they run tests. By the third they ask whether there’s a lot of stress at home.’ Sociologists have described what that turn does: legitimacy sits at the center of living with symptomsSubjective experiences reported by the patient (e.g., nausea, fatigue). medicine cannot explain, and ‘society does not readily grant permission to be ill in the absence of disease.’ Honesty flag: the visit count is Stina’s own account and no entry dates the visits; the module does not say her pain had no psychological part — it says a fever and a white count up are organic findings.	Nettleton 2006 (as cited in the diary’s evidence section)	Qualitative research — moderate

A teenager with fever and pain low on the right has a wide differential, and the first answer every emergency room has to rule out is appendicitis — it is common, and missing it is dangerous. ‘Unremarkable’ is not a diagnosis: when an appendix comes out normal, the pain still needs an explanation, and pain that comes back in the same place after the appendix is gone needs one most of all. These are the neighbors to keep in mind.

Links checked September 2026.

1. Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010;10:826–837.

2. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009;27:621–668.

3. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptorA structure that detects stimuli., TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97:133–144 (PubMed 10199409).

4. Lidar M, Doron A, Kedem R, Yosepovich A, Langevitz P, Livneh A. Appendectomy in familial Mediterranean fever: clinical, genetic and pathological findings. Clin Exp Rheumatol 2008;26(4):568–573 (PubMed 18799086).

5. Xu H, Yang J, Gao W, et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 2014;513:237–241 (PubMed 24919149).

6. Park YH, Wood G, Kastner DL, Chae JJ. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol 2016;17(8):914–921 (PubMed 27270401).

7. Gao W, Yang J, Liu W, Wang Y, Shao F. Site-specific phosphorylationaddition of a high-energy phosphate to a compound, usually a metabolic intermediate, a protein, or A and microtubule dynamics control Pyrin inflammasome activation. Proc Natl Acad Sci USA 2016;113(33):E4857–E4866 (PubMed 27482109).

8. Van Gorp H, Saavedra PHV, de Vasconcelos NM, et al. Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation. Proc Natl Acad Sci USA 2016;113(50):14384–14389 (PubMed 27911804).

9. Magnotti F, Lefeuvre L, Benezech S, et al. Pyrin dephosphorylation is sufficient to trigger inflammasome activation in familial Mediterranean fever patients. EMBO Mol Med 2019;11(11):e10547 (PubMed 31589380).

10. Heilig R, Broz P. Function and mechanism of the pyrin inflammasome. Eur J Immunol 2018;48(2):230–238 (PubMed 29148036).

11. Auron PE, et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci USA 1984;81:7907–7911.

12. Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 2015;526:660–665 (PubMed 26375003).

13. Kayagaki N, Stowe IB, Lee BL, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 2015;526:666–671.

14. Evavold CL, et al. The pore-forming protein gasdermin D regulates interleukin-1 secretion from living macrophages. Immunity 2018;48(1):35–44.e6 (PubMed 29195811).

15. Muñoz-Planillo R, et al. K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 2013;38(6):1142–1153 (PubMed 23809161).

16. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–454.

17. COLCRYS (colchicine, USP) tablets — prescribing information, US Food and Drug Administration label (NDA 022352): Contraindications; Warnings 5.3 (fatal interactions with P-gp and strong CYP3A4 inhibitors) and 5.4 (neuromuscular toxicity and rhabdomyolysis; statins and fibrates may potentiate myopathy).

18. Terkeltaub RA, et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum 2011;63(8):2226–2237 (PubMed 21480191).

19. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2016;134(21):e468–e495 (PubMed 27754879).

20. Ozen S, Sag E, Oton T, et al. EULAR/PReS endorsed recommendations for the management of familial Mediterranean fever (FMF): 2024 update. Ann Rheum Dis 2025;84(6):899–909 (PubMed 40234174).

21. Batu Akal ED, Bayindir Y, Sener S, et al. A treatment algorithm for familial Mediterranean fever patients with menstruation-associated attacks. Rheumatology (Oxford) 2025;64(3):1341–1346 (published online 2024; doi:10.1093/rheumatology/keae256).

22. Ben-Chetrit E, Ben-Chetrit A. Familial Mediterranean fever and menstruation. BJOG 2001;108(4):403–407 (PubMed 11305548).

23. Alvarado A. A practical score for the early diagnosis of acute appendicitis. Ann Emerg Med 1986;15(5):557–564 (PubMed 3963537).

24. Nettleton S. ‘I just want permission to be ill’: towards a sociology of medically unexplained symptoms. Soc Sci Med 2006;62(5):1167–1178 (as cited in the diary’s evidence section).

25. The French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997;17:25–31.

26. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997;90:797–807.

27. Familial Mediterranean Fever. GeneReviews®, NCBI Bookshelf NBK1227 (PubMed 20301405). University of Washington, Seattle (initial posting 2000; revised since).

28. Lancieri M, Bustaffa M, Palmeri S, et al. An update on familial Mediterranean fever. Int J Mol Sci 2023;24(11):9584 (PubMed 37298536).

29. Infevers: the registry of hereditary autoinflammatory disorder mutations — MEFV (variant classifications).

30. OpenStax Anatomy & Physiology 2e: Chapter 3 (The Cellular Level of Organization), Chapter 12 (The Nervous System and Nervous Tissue), Chapter 18 (The Cardiovascular System: Blood), Chapter 20 (The Cardiovascular System: Blood Vessels and Circulation), Chapter 21 (The Lymphatic and Immune System), Chapter 26 (Fluid, Electrolyte, and Acid–Base Balance).

Standing reference anchors: EULAR/PReS FMF management: 2024 update · GeneReviews: FMF · Infevers — MEFV registry